ESMO Direct Strike Unresectable NSCLC: After IMRT, Duvalizumab is 80% used!

Editor: Xiaoyuan

Medical pulse through the collation, unauthorized please do not reprint!

The European Society for Internal Oncology (ESMO) Annual Meeting is the most prestigious and influential oncology conference
in Europe.

Prior to the approval of dulvalizumab, Japanese researchers had demonstrated the feasibility of intensity-modulated conformal radiotherapy (IMRT) combined with chemotherapy for locally advanced NSCLC, which is currently used for thoracic chemoradiotherapy (CRT), but there are few
prospective data on intensity-modulated conformal radiotherapy (IMRT) combined chemotherapy sequential-tuvalizumab.

1 Background

Based on the PACIFIC study, consolidation of dravirizumab after chemoradiotherapy became the standard of care for
patients with locally advanced NSCLC.

2 Methods

Eligible patients are cytically or histically confirmed non-resectable locally advanced NSCLCs: patients with PS 0/1, age <75, and no serious complications are treated with
IMRT (60Gy/30Fr).

Study the design

3 Results

Between November 2019 and February 2021, a total of 32 patients were enrolled, of which 2 patients withdrew informed consent and 24 of the 30 patients received dulvalizumab treatment (80.

Figure PFS and OS results in compliance with the protocol population (PPP).

The 1-year PFS and OS rates are 55% and 91%,
respectively.
There were no treatment-related deaths and no grade 4 adverse events
.
The incidence of pneumonia and major adverse events are shown in the table
.

Table Radiation dose and incidence of pneumonia

Table Major adverse events

4 Discussion and conclusion

Previous studies have shown that the proportion of patients who are not suitable for duvalizumab after deterministic CRT is 23-30%.

The study showed that the use rate of dulvalizumab after IMRT combined chemotherapy was 80%, and the reasons for not receiving dullizumab after IMRT combined chemotherapy (independent of the treatment outcome) included that one patient participated in other studies and another patient received 3D-CRT
due to disease instability.
IMRT combined with chemotherapy sequentivarizumab showed good safety and a low
incidence of severe pneumonia.
Some patients due to disease progression or adverse events cannot be treated
with dulliumab.
Only a few patients due to AE or disease progression during treatment
cannot receive dulvalizumab.
IMRT in combination with chemotherapy sequentivaririzumab has shown a viable safety
.
References

958P-Intensity-modulated radiotherapy （IMRT）-adapted chemoradiotherapy （CRT） followed by durvalumab for locally advanced non-small cell lung cancer （NSCLC）: A multicenter prospective observational study （WJOG12019L）.
2022 ESMO.